Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuprolide Acetate 45 mg 6-Month Depot in Children With CPP
NCT03695237Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2018
- Primary completion
- May 2021
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of leuprolide in central precocious puberty (CPP), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants With Suppression of Peak GnRHa-Stimulated Luteinizing Hormone (LH) to Less Than 4 mlU/mL at Week 24. Started Oct 2018; status: completed.
02
Drugs
leuprolide
03
Conditions
central precocious puberty (CPP)
Beyond the preview
Go deeper on NCT03695237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03695237.